Press releases
- Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023
- Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors
- Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer
Key statistics
On Monday, Relmada Therapeutics Inc (4E2:DEU) closed at 2.32, 14.85% above the 52 week low of 2.02 set on Dec 09, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.26 |
---|---|
High | 2.32 |
Low | 2.24 |
Bid | 2.22 |
Offer | 2.30 |
Previous close | 2.32 |
Average volume | 50.00 |
---|---|
Shares outstanding | 30.10m |
Free float | 29.71m |
P/E (TTM) | -- |
Market cap | 74.35m USD |
EPS (TTM) | -5.85 USD |
Data delayed at least 15 minutes, as of Mar 20 2023 11:26 BST.
More ▼